JBIO Jade Biosciences
Price Chart
Executive Summary
Jade Biosciences closed a public offering of 11.5M shares at $15.00/share, raising $172.5M in gross proceeds. The proceeds will fund clinical trials, preclinical studies, and manufacturing for its autoimmune pipeline, including lead candidate JADE101 for IgA nephropathy. The offering represents significant dilution (~13% of pre-offer shares based on market cap) but provides a substantial cash runway for a clinical-stage biotech.
Key Financial Metrics
Actionable Insight
The offering provides a strong cash runway for a clinical-stage biotech, reducing near-term financing risk, but the dilution is material. Monitor upcoming clinical data readouts for JADE101 (APRIL-targeting in IgA nephropathy) as the primary catalyst; the cash extends the runway but does not change the binary risk of pipeline failure.
Key Facts
- Closed public offering of 11,500,000 shares at $15.00 per share
- Gross proceeds of $172.5 million
- Underwriters' option for 1,500,000 additional shares fully exercised
- Offered under shelf registration statement on Form S-3 effective May 15, 2026
- Proceeds to fund clinical trials, preclinical studies, manufacturing, R&D, and general corporate purposes
- Lead candidate JADE101 targets APRIL for IgA nephropathy; pipeline includes JADE201 (anti-BAFF-R) and JADE301 (undisclosed)
Financial Impact
Dilution of approximately 13% based on pre-offering market cap of $876M; $172.5M gross proceeds added to cash balance
Risk Factors
- Significant dilution to existing shareholders (~13%)
- Clinical-stage company with no approved products; pipeline risk is binary
- Proceeds used for general corporate purposes, not tied to specific near-term catalyst
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3307597 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 5, 2026
7d ago
|
Press Release
| $16.91 awaiting T+1 | awaiting T+1 | — | $15.34 (+9.28%) |
|
Jun 4, 2026
8d ago
|
8-K
| $17.52 awaiting T+1 | awaiting T+1 | — | $15.34 (+12.44%) |
|
Jun 4, 2026
8d ago
|
424B5
| $17.52 awaiting T+1 | awaiting T+1 | — | $15.34 (+12.44%) |
|
Jun 4, 2026
9d ago
|
Press Release
| $17.74 $16.94 | ▲ +4.51% | ▲ +1.91% | $15.34 (+13.53%) |
|
Jun 3, 2026
9d ago
|
424B5
| $17.74 $16.94 | ▲ +4.51% | ▲ +1.94% | $15.34 (+13.53%) |
|
Jun 3, 2026
9d ago
|
Press Release
| $17.74 $16.94 | ▲ +4.51% | ▲ +1.94% | $15.34 (+13.53%) |
|
Jun 1, 2026
11d ago
|
8-K
| $18.59 $17.75 | ▼ −4.52% | ▼ −4.66% | $15.34 (−17.48%) |
|
May 26, 2026
17d ago
|
Press Release
| $21.50 $20.84 | ▼ −3.07% | ▼ −3.62% | $15.34 (−28.65%) |
|
May 18, 2026
26d ago
|
EFFECT
| $22.01 $21.88 | ▲ +0.59% | ▼ −0.06% | $15.34 (+30.30%) |
|
May 7, 2026
5w ago
|
S-3
| $25.81 $24.86 | ▲ +3.68% | ▲ +3.91% | $15.34 (+40.57%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access